ロード中...
Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report
A 35-year-old male was diagnosed with chronic myeloid leukemia in the chronic phase and was prescribed 100 mg daily dasatinib. However, dasatinib was discontinued due to thrombocytopenia, and within six months, the disease progressed to the lymphoid blastic phase. Hyper-cyclophosphamide, vincristine...
保存先:
| 出版年: | Oncol Lett |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
D.A. Spandidos
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5452986/ https://ncbi.nlm.nih.gov/pubmed/28599428 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.5989 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|